Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Postoperative chemoradiotherapy is the recommended standard therapy for patients with locally advanced rectal cancer. In recent years, encouraging results with preoperative radiotherapy have been reported. We compared preoperative chemoradiotherapy with postoperative chemoradiotherapy for locally advanced rectal cancer. METHODS: We randomly assigned patients with clinical stage T3 or T4 or node-positive disease to receive either preoperative or postoperative chemoradiotherapy. The preoperative treatment consisted of 5040 cGy delivered in fractions of 180 cGy per day, five days per week, and fluorouracil, given in a 120-hour continuous intravenous infusion at a dose of 1000 mg per square meter of body-surface area per day during the first and fifth weeks of radiotherapy. Surgery was performed six weeks after the completion of chemoradiotherapy. One month after surgery, four five-day cycles of fluorouracil (500 mg per square meter per day) were given. Chemoradiotherapy was identical in the postoperative-treatment group, except for the delivery of a boost of 540 cGy. The primary end point was overall survival. RESULTS: Four hundred twenty-one patients were randomly assigned to receive preoperative chemoradiotherapy and 402 patients to receive postoperative chemoradiotherapy. The overall five-year survival rates were 76 percent and 74 percent, respectively (P=0.80). The five-year cumulative incidence of local relapse was 6 percent for patients assigned to preoperative chemoradiotherapy and 13 percent in the postoperative-treatment group (P=0.006). Grade 3 or 4 acute toxic effects occurred in 27 percent of the patients in the preoperative-treatment group, as compared with 40 percent of the patients in the postoperative-treatment group (P=0.001); the corresponding rates of long-term toxic effects were 14 percent and 24 percent, respectively (P=0.01). CONCLUSIONS: Preoperative chemoradiotherapy, as compared with postoperative chemoradiotherapy, improved local control and was associated with reduced toxicity but did not improve overall survival.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among the patients in whom abdominoperineal resection (APR) was considered necessary at the time of enrollment, the percentage of patients in whom sphincter preservation was possible was significantly higher in the preoperative chemoradiotherapy group [119].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“there was no significant difference in the 5-year survival rate”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
In the citing paper
“but the local recurrence rate and incidence of grade 3 or higher adverse events were significantly lower in the preoperative chemoradiotherapy group.”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [119]
Citations
Cites
Statistical Methods in Cancer Research
Breslow, N. E. (1980) · Cited by 7,332
Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Effective Surgical Adjuvant Therapy for High-Risk Rectal Carcinoma
Krook, J. E., Moertel, C. G., Gunderson, L. L., Wieand, H. S., Collins, R. T., Beart, R. W., Kubista, T. P., Poon, M. A., Meyers, W. C., Mailliard, J. A., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103143241101 · Cited by 1,879
Statistical methods in cancer research. Vol. 1. The analysis of case-control studies
(1983) · Food and Chemical Toxicology · doi:10.1016/0278-6915(83)90281-8 · Cited by 1,716
Prolongation of the Disease-Free Interval in Surgically Treated Rectal Carcinoma
Gastrointestinal Tumor Study Group (1985) · New England Journal of Medicine · doi:10.1056/nejm198506063122301 · Cited by 1,130
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Hyams, D. M., Mamounas, E. P., Petrelli, N., Rockette, H., Jones, J., Wieand, S. H., Deutsch, M., Wickerham, L. D., Fisher, B., & Wolmark, N. (1997) · Diseases of the Colon & Rectum · doi:10.1007/bf02054976 · Cited by 360
Research works printed but not linked: 3
- Seegenschmiedt MH, 1993, Strahlenther Onkol, 169, 83
- Pichlmaier H, 1994, Chirurg, 65, 411
- Hermanek P. What can the pathologist tell the surgeon about rectal cancer resection? In: Scholefield JH, ed. Challenges in colorectal cancer. Oxford, England: Blackwell, 2000:81-90.
Cited by
Items 201–300 of 1,004
Bando, H., Tsukada, Y., Inamori, K., Togashi, Y., Koyama, S., Kotani, D., Fukuoka, S., Yuki, S., Komatsu, Y., Homma, S., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3213 · Cited by 170
“2, 3) has been performed as the standard treatment to reduce the risk of local recurrence (4).”
BackgroundDayde, D., Tanaka, I., Jain, R., Tai, M., & Taguchi, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18030573 · Cited by 180
Akiyoshi, T., Matsueda, K., Hiratsuka, M., Unno, T., Nagata, J., Nagasaki, T., Konishi, T., Fujimoto, Y., Nagayama, S., Fukunaga, Y., et al. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4565-5 · Cited by 179
Dalton, R. S. J., Velineni, R., Osborne, M. E., Thomas, R., Harries, S., Gee, A. S., & Daniels, I. R. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2011.02752.x · Cited by 179
S3-Leitlinie Kolorektales Karzinom Version 1.0 - Juni 2013 AWMF-Registernummer: 021/007OL
Pox, C., Aretz, S., Bischoff, S., Graeven, U., Hass, M., Heußner, P., Hohenberger, W., Holstege, A., Hübner, J., Kolligs, F., et al. (2013) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0033-1350264 · Cited by 179
Self-citationRex, D. K., Kahi, C. J., Levin, B., Smith, R. A., Bond, J. H., Brooks, D., Burt, R. W., Byers, T., Fletcher, R. H., Hyman, N., et al. (2006) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.56.3.160 · Cited by 167
The Rectal Cancer microRNAome – microRNA Expression in Rectal Cancer and Matched Normal Mucosa
Gaedcke, J., Grade, M., Camps, J., Søkilde, R., Kaczkowski, B., Schetter, A. J., Difilippantonio, M. J., Harris, C. C., Ghadimi, B. M., Møller, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0016 · Cited by 179
“All patients were enrolled or treated according to theCAO/ARO/AIO-94 (3) and CAO/ARO/AIO-04 trial of the German Rectal Cancer Study Group.”
MethodPucciarelli, S., De Paoli, A., Guerrieri, M., La Torre, G., Maretto, I., De Marchi, F., Mantello, G., Gambacorta, M. A., Canzonieri, V., Nitti, D., et al. (2013) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e3182a2303e · Cited by 175
Maréchal, R., Vos, B., Polus, M., Delaunoit, T., Peeters, M., Demetter, P., Hendlisz, A., Demols, A., Franchimont, D., Verset, G., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr473 · Cited by 176
“Previous reports have shown advantages to neoadjuvant chemoradiotherapy (CRT) in downstaging large tumors and in improving local tumor control, resulting in a local relapse rate of <10% after 5 years [3–7].”
ResultSamuelian, J. M., Callister, M. D., Ashman, J. B., Young-Fadok, T. M., Borad, M. J., & Gunderson, L. L. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2011.01.051 · Cited by 173
“Furthermore, the pCR rate of both groups compare favorably to published rates of 8–15% from randomized trials using similar doses of preoperative RT with 5-FU–based chemotherapy (2, 3, 31, 32).”
BackgroundMethodResultInfluentialHalabi, W. J., Jafari, M. D., Nguyen, V. Q., Carmichael, J. C., Mills, S., Pigazzi, A., & Stamos, M. J. (2014) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000033 · Cited by 171
Guillem, J. G., Chessin, D. B., Shia, J., Moore, H. G., Mazumdar, M., Bernard, B., Paty, P. B., Saltz, L., Minsky, B. D., Weiser, M. R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.114 · Cited by 172
The future of the TNM staging system in colorectal cancer: time for a debate?
Quirke, P., Williams, G. T., Ectors, N., Ensari, A., Piard, F., & Nagtegaal, I. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70205-x · Cited by 173
Mace, A. G., Pai, R. K., Stocchi, L., & Kalady, M. F. (2015) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000266 · Cited by 170
Laparoscopic vs open resection for rectal cancer: a meta‐analysis of randomized clinical trials
Trastulli, S., Cirocchi, R., Listorti, C., Cavaliere, D., Avenia, N., Gullà, N., Giustozzi, G., Sciannameo, F., Noya, G., & Boselli, C. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.02985.x · Cited by 171
Stipa, F., Chessin, D. B., Shia, J., Paty, P. B., Weiser, M., Temple, L. K. F., Minsky, B. D., Wong, W. D., & Guillem, J. G. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.03.053 · Cited by 173
“0001 Local and distant recurrence 0 (0) 2 (1) N.”
BackgroundSarcopenia is negatively associated with long‐term outcomes in locally advanced rectal cancer
Choi, M. H., Oh, S. N., Lee, I. K., Oh, S. T., & Won, D. D. (2018) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.12234 · Cited by 170
“Locally advanced rectal cancer is usually treated with preoperative chemoradiation followed by curative resection with total mesorectal excision.(8,9) Adjuvant chemotherapy is generally performed to removemicrometastases.”
BackgroundKuo, L.-J., Liu, M.-C., Jian, J. J.-M., Horng, C.-F., Cheng, T.-I., Chen, C.-M., Fang, W.-T., & Chung, Y.-L. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9471-z · Cited by 169
“German Rectal Cancer Group demonstrated that preoperative neoadjuvant chemoradiation therapy improved local control and reduced radiation toxicity, but had no overall survival benefit compared with postoperative adjuvant chemoradiotherapy.(11)”
BackgroundLahaye, M. J., Engelen, S. M. E., Kessels, A. G. H., de Bruïne, A. P., von Meyenfeldt, M. F., van Engelshoven, J. M. A., van de Velde, C. J. H., Beets, G. L., & Beets-Tan, R. G. H. (2008) · Radiology · doi:10.1148/radiol.2463070221 · Cited by 169
Perez, R. O., Habr-Gama, A., São Julião, G. P., Proscurshim, I., Neto, A. S., & Gama-Rodrigues, J. (2011) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e3182083b84 · Cited by 166
“Even though prospective randomized studies have showed no differences in the incidence of anastomotic leaks, several retrospective analyses of large series of patients have identified the use of preoperative radiation therapy as one of the significant predictors of clinically relevant leaks.(1,20,21) Complications aft…”
BackgroundResultDas, P., Skibber, J. M., Rodriguez-Bigas, M. A., Feig, B. W., Chang, G. J., Hoff, P. M., Eng, C., Wolff, R. A., JanJan, N. A., Delclos, M. E., et al. (2006) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000214930.78200.4a · Cited by 166
The importance of MRI for rectal cancer evaluation
Fernandes, M. C., Gollub, M. J., & Brown, G. (2022) · Surgical Oncology · doi:10.1016/j.suronc.2022.101739 · Cited by 164
Qin, Q., Ma, T., Deng, Y., Zheng, J., Zhou, Z., Wang, H., Wang, L., & Wang, J. (2016) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000000665 · Cited by 164
Dresen, R. C., Beets, G. L., Rutten, H. J. T., Engelen, S. M. E., Lahaye, M. J., Vliegen, R. F. A., de Bruïne, A. P., Kessels, A. G. H., Lammering, G., & Beets-Tan, R. G. H. (2009) · Radiology · doi:10.1148/radiol.2521081200 · Cited by 167
‘Liver First’ Approach in the Treatment of Colorectal Cancer with Synchronous Liver Metastases
Mentha, G., Roth, A. D., Terraz, S., Giostra, E., Gervaz, P., Andres, A., Morel, P., Rubbia-Brandt, L., & Majno, P. E. (2008) · Digestive Surgery · doi:10.1159/000184734 · Cited by 165
“especially in patients with stage IV CR cancer. The realism of our assumptions on the risk of a period without chemotherapy if the primary was resected first was demonstrated by a randomized study, showing that only one half of patients with rectal cancer could have a full dose of the postoperative chemotherapy, for w…”
BackgroundManceau, G., Karoui, M., Werner, A., Mortensen, N. J., & Hannoun, L. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70378-9 · Cited by 163
FDG PET/CT radiomics for predicting the outcome of locally advanced rectal cancer
Lovinfosse, P., Polus, M., Van Daele, D., Martinive, P., Daenen, F., Hatt, M., Visvikis, D., Koopmansch, B., Lambert, F., Coimbra, C., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3855-5 · Cited by 165
“Patients achieving a pCR could benefit from improved local control, a facilitated surgery and a sphincter-saving procedure for those with low-lying tumors [51, 52].”
BackgroundBujko, K., Glynne-Jones, R., & Bujko, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq054 · Cited by 164
“Randomised trials have shown better local control, lower toxicity (both acute and late), and higher compliance if preoperative short-course radiotherapy or conventionally fractionated chemoradiation is administered rather than postoperative conventionally fractionated radiochemotherapy [1, 2].”
BackgroundSmalley, S. R., Benedetti, J. K., Williamson, S. K., Robertson, J. M., Estes, N. C., Maher, T., Fisher, B., Rich, T. A., Martenson, J. A., Kugler, J. W., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.9544 · Cited by 164
Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials
George, T. J., Allegra, C. J., & Yothers, G. (2015) · Current Colorectal Cancer Reports · doi:10.1007/s11888-015-0285-2 · Cited by 161
Hong, Y. S., Kim, S. Y., Lee, J. S., Nam, B.-H., Kim, K.-P., Kim, J. E., Park, Y. S., Park, J. O., Baek, J. Y., Kim, T.-Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00016 · Cited by 163
Pietrzak, L., Bujko, K., Nowacki, M. P., Kepka, L., Oledzki, J., Rutkowski, A., Szmeja, J., Kladny, J., Dymecki, D., Wieczorek, A., et al. (2007) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2007.07.007 · Cited by 162
“Two randomised trials have demonstrated that preoperative radiotherapy is superior to postoperative radiotherapy in terms of local recurrence risk reduction and toxicity [7,16].”
BackgroundConcurrent Chemoradiotherapy in Resected Extrahepatic Cholangiocarcinoma
Nelson, J. W., Ghafoori, A. P., Willett, C. G., Tyler, D. S., Pappas, T. N., Clary, B. M., Hurwitz, H. I., Bendell, J. C., Morse, M. A., Clough, R. W., et al. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2008.07.008 · Cited by 161
Morino, M., Risio, M., Bach, S., Beets-Tan, R., Bujko, K., Panis, Y., Quirke, P., Rembacken, B., Rullier, E., Saito, Y., et al. (2015) · Surgical Endoscopy · doi:10.1007/s00464-015-4067-3 · Cited by 162
Oncologic Outcomes of Robotic-Assisted Total Mesorectal Excision for the Treatment of Rectal Cancer
Baek, J.-H., McKenzie, S., Garcia-Aguilar, J., & Pigazzi, A. (2010) · Annals of Surgery · doi:10.1097/sla.0b013e3181c79114 · Cited by 161
“The 5-year overall and disease free-survival after open rectal surgery in patients who underwent preoperative chemoradiotherapy was 76% and 68%, respectively.(35) The 3-year overall and disease-free survivals in our study were comparable to those of previous study of laparoscopic and open rectal surgery (Table 4).”
ResultNogué, M., Salud, A., Vicente, P., Arriví, A., Roca, J. M., Losa, F., Ponce, J., Safont, M. J., Guasch, I., Moreno, I., et al. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0285 · Cited by 158
MiR-106b induces cell radioresistance via the PTEN/PI3K/AKT pathways and p21 in colorectal cancer
Zheng, L., Zhang, Y., Liu, Y., Zhou, M., Lu, Y., Yuan, L., Zhang, C., Hong, M., Wang, S., & Li, X. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0592-z · Cited by 158
“A short-term regimen of high-dose preoperative radiotherapy reduces the rate of local recurrence and improves survival among patients with resectable rectal cancer [1].”
BackgroundMarco, M. R., Zhou, L., Patil, S., Marcet, J. E., Varma, M. G., Oommen, S., Cataldo, P. A., Hunt, S. R., Kumar, A., Herzig, D. O., et al. (2018) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000001207 · Cited by 159
Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer
Marín, J. J. G., de Medina, F. S., Castaño, B., Bujanda, L., Romero, M. R., Martínez‐Augustin, O., del Moral-Ávila, R., & Briz, Ó. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.638303 · Cited by 169
“The adjuvant radiation management approach has been shifting toward preoperative therapy to promote sphincter-preserving surgery and decrease acute and late bowel toxicity (Sauer et al., 2004).”
BackgroundArbea, L., Ramos, L. I., Martínez-Monge, R., Moreno, M., & Aristu, J. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-17 · Cited by 158
“Preoperative chemoradiation (CRT) is the standard neoadjuvant treatment in patients with LARC (T3 and/or N+) [1].”
BackgroundMonson, J. R. T., Probst, C. P., Wexner, S. D., Remzi, F. H., Fleshman, J. W., García‐Aguilar, J., Chang, G. J., & Dietz, D. W. (2014) · Annals of Surgery · doi:10.1097/sla.0000000000000928 · Cited by 162
Serna, G., Ruiz-Pace, F., Hernando, J., Alonso, L., Fasani, R., Landolfi, S., Comas, R., Jimenez, J., Elez, E., Bullman, S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.003 · Cited by 155
“Patients receiving radiation therapy and fluoropyrimidinebased concurrent nCRT show improved rates of tumor downstaging and local control.(1) Multiple studies have”
BackgroundAccuracy of Gadofosveset-enhanced MRI for Nodal Staging and Restaging in Rectal Cancer
Lambregts, D. M. J., Beets, G. L., Maas, M., Kessels, A. G. H., Bakers, F. C. H., Cappendijk, V. C., Engelen, S. M. E., Lahaye, M. J., de Bruïne, A. P., Lammering, G., et al. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e31820b01f1 · Cited by 156
Principles of cancer treatment by chemotherapy
Dickens, E., & Ahmed, S. I. (2018) · Surgery (Oxford) · doi:10.1016/j.mpsur.2017.12.002 · Cited by 169
Chen, G., Jin, Y., Guan, W., Zhang, R., Xiao, W., Cai, P., Liu, M., Lin, J., Wang, F., Li, C., et al. (2023) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00439-3 · Cited by 162
Bringing the heavy: carbon ion therapy in the radiobiological and clinical context
Schlaff, C. D., Krauze, A. V., Belard, A., O’Connell, J. J., & Camphausen, K. A. (2014) · Radiation Oncology · doi:10.1186/1748-717x-9-88 · Cited by 160
Robertson, J. M., Lockman, D. M., Yan, D., & Wallace, M. F. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.06.066 · Cited by 152
Park, J., Yoon, S. M., Yu, C. S., Kim, J. H., Kim, T. W., & Kim, J. C. (2011) · Cancer · doi:10.1002/cncr.25943 · Cited by 160
“We could not enroll the planned number of patients because patient accrual decreased after publication of the study by Sauer et al.(2) In addition, randomization could have been affected by investigator preference for preoperative treatment for low-lying tumors; hence, we closed this protocol earlier than initially pl…”
BackgroundMethodResultInfluentialIto, M., Saito, N., Sugito, M., Kobayashi, A., Nishizawa, Y., & Tsunoda, Y. (2009) · Diseases of the Colon & Rectum · doi:10.1007/dcr.0b013e31819739a0 · Cited by 152
“Incontinence of loose stools 34/88 (39) 22/84 (26) 20/74 (27) 14/60 (23)* Incontinence of solid stools 24/88 (27) 18/84 (21) 17/74 (23) 10/60 (17)”
InfluentialRectum-conserving surgery in the era of chemoradiotherapy
Smith, F. M., Waldron, D. J., & Winter, D. C. (2010) · British journal of surgery · doi:10.1002/bjs.7251 · Cited by 149
Basch, E., Dueck, A. C., Mitchell, S. A., Mamon, H. J., Weiser, M. R., Saltz, L. B., Gollub, M. J., Rogak, L. J., Ginos, B., Mazza, G. L., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00903 · Cited by 151
Hasan, S., Renz, P. B., Wegner, R. E., Finley, G. G., Raj, M. S., Monga, D. K., McCormick, J., & Kirichenko, A. V. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000003051 · Cited by 157
Boldrini, L., Cusumano, D., Chiloiro, G., Casà, C., Masciocchi, C., Lenkowicz, J., Cellini, F., Dinapoli, N., Azario, L., Teodoli, S., et al. (2019) · La radiologia medica · doi:10.1007/s11547-018-0951-y · Cited by 147
Machiels, J.-P., Sempoux, C. L., Scalliet, P. G. M., Coche, J.-C., Humblet, Y., Cutsem, E. V., Kerger, J. N., Canon, J.-L., Peeters, M., Aydın, S., et al. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl460 · Cited by 147
“The German Rectal Cancer Study Group reported that preoperative chemoradiation improves local control and sphincter preservation and is associated with reduced toxicity but does not improve survival compared with postoperative therapy [12].”
BackgroundReview of randomised trials using the post-randomised consent (Zelen's) design
Adamson, J., Cockayne, S., Puffer, S., & Torgerson, D. J. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.11.003 · Cited by 160
“[61] Pre- vs.”
de Campos‐Lobato, L. F., Geisler, D. P., Moreira, A. D. L., Stocchi, L., Dietz, D., & Kalady, M. F. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1197-8 · Cited by 149
“This approach is associated reduced with local recurrence and increased treatment compliance compared to postoperative chemoradiation.(5) In 1999, François et al.”
Montroni, I., Ugolini, G., Saur, N. M., Spinelli, A., Rostoft, S., Millán, M., Wolthuis, A. M., Daniels, I. R., Hompes, R., Penna, M., et al. (2018) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2018.08.003 · Cited by 165
Radiation Therapy for Rectal Cancer: Executive Summary of an ASTRO Clinical Practice Guideline
Wo, J. Y.-L., Anker, C. J., Ashman, J. B., Bhadkamkar, N. A., Bradfield, L., Chang, D. T., Dorth, J. A., García‐Aguilar, J., Goff, D. C., Jacqmin, D. J., et al. (2020) · Practical Radiation Oncology · doi:10.1016/j.prro.2020.08.004 · Cited by 160
Benson, A. B., Bekaii‐Saab, T., Chan, E. W., Chen, Y., Choti, M. A., Cooper, H. S., Engstrom, P. F., Enzinger, P. C., Fakih, M., Fuchs, C. S., et al. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0158 · Cited by 163
Sohn, B., Lim, J. S., Kim, H., Myoung, S., Choi, J., Kim, N. K., & Kim, M. (2014) · European Radiology · doi:10.1007/s00330-014-3527-9 · Cited by 149
“Recently, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by total mesorectal excision (TME) has become the widely accepted treatment for rectal cancer, rather than surgery followed by CCRT. Neoadjuvant CCRT was demonstrated to have better local control and less toxicity than postoperative CCRT [15, 16].”
BackgroundInfluentialTho, L. M., Glegg, M., Paterson, J., Yap, C., MacLeod, A., McCabe, M., & McDonald, A. C. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2006.05.005 · Cited by 143
Rödel, C. M., Arnold, D., Hipp, M., Liersch, T., Dellas, K., Iesalnieks, I., Hermann, R. M., Lordick, F., Hinke, A., Hohenberger, W., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.07.2356 · Cited by 148
Self-citationManagement of colorectal cancer
Stintzing, S. (2014) · F1000Prime Reports · doi:10.12703/p6-108 · Cited by 190
Total pelvic exenteration for primary locally advanced and locally recurrent rectal cancer
Vermaas, M., Ferenschild, F. T. J., Verhoef, C. K., Nuyttens, J. J. M. E., Marinelli, A. W. K. S., Wiggers, T., Kirkels, W. J., Eggermont, A. M. M., & de Wilt, J. H. W. (2006) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2006.09.021 · Cited by 143
D’Souza, N., Babberich, M. P. M. D. N. T., D’Hoore, A. J. L., Tiret, E., Xynos, E., Beets‐Tan, R. G. H., Nagtegaal, I. D., Blomqvist, L., Holm, T., Glimelius, B. L. G., et al. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003251 · Cited by 148
Aschele, C., Friso, M. L., Pucciarelli, S., Lonardi, S., Sartor, L., Fabris, G., Urso, E. D. L., Bianco, P. D., Sotti, G., Lise, M., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi212 · Cited by 148
“Although the best sequence of surgery, radiation and chemotherapy remains to be determined, recent data indicate that preoperative chemoradiation significantly improves local control, acute and late toxicity and the rates of sphincter-preserving surgeries as compared to postoperative chemoradiation [11].”
Kalff, V., Duong, C., Drummond, E. G. P., Matthews, J. P., & Hicks, R. J. (2006) · PubMed · Cited by 142
Wu, Y. H., Liang, Y., Wei, K., Li, W., Yao, M., Zhang, J., & Grinshpun, S. A. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.03322-14 · Cited by 148
Giannini, V., Mazzetti, S., Bertotto, I., Chiarenza, C., Cauda, S., Delmastro, E., Bracco, C., Dia, A. D., Leone, F., Médico, E., et al. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4250-6 · Cited by 148
Ceelen, W. P., Fierens, K., Nieuwenhove, Y. V., & Pattyn, P. (2008) · International Journal of Cancer · doi:10.1002/ijc.24247 · Cited by 162
“The theoretical superiority of preoperative versus postoperative combined modality therapy has been confirmed by the German rectal cancer trial.(10) The effect of preoperative RT on local recurrence rate is consistent even when optimal surgical technique (TME) is implemented.”
ResultKitayama, J., Yasuda, K., Kawai, K., Sunami, E., & Nagawa, H. (2010) · Radiation Oncology · doi:10.1186/1748-717x-5-47 · Cited by 144
“Findings Preoperative chemoradiotherapy (CRT) is currently used worldwide as the initial treatment for advanced RC, since it can produce down-staging in approximately half of patients with locally advanced rectal cancer RC, resulting in a lower rate of postoperative local recurrence and a higher rate of sphincter-pres…”
BackgroundFokas, E., Ströbel, P., Fietkau, R., Ghadimi, M. B., Liersch, T., Grabenbauer, G. G., Hartmann, A., Kaufmann, M., Sauer, R., Graeven, U., et al. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx095 · Cited by 155
Self-citationBrush, J. P., Boyd, K., Chappell, F. M., Crawford, F., Dozier, M., Fenwick, E. A. L., Glanville, J., McIntosh, H., Renehan, A. G., Weller, D., et al. (2011) · Health Technology Assessment · doi:10.3310/hta15350 · Cited by 162
Smith, F. M., Chang, K. H., Sheahan, K. D., Hyland, J. M., O’Connell, P. R., & Winter, D. C. (2012) · British journal of surgery · doi:10.1002/bjs.8700 · Cited by 141
Hur, H., Oh, C., Won, Y., Oh, J. H., & Kim, N. K. (2018) · Annals of Coloproctology · doi:10.3393/ac.2018.08.02.1 · Cited by 140
“Furthermore, advances in pre- and postoperative adjuvant treatments, including chemotherapy and radiotherapy, have increased radical resection rates and decreased local recurrence rates in patients with CRC [22].”
BackgroundGollins, S., Moran, B. J., Adams, R., Cunningham, C., Bach, S. P., Myint, A. S., Renehan, A. G., Karandikar, S. S., Goh, V., Prezzi, D., et al. (2017) · Colorectal Disease · doi:10.1111/codi.13705 · Cited by 153
“01), including chronic diarrhoea, small bowel obstruction and anastomotic strictures (Sauer et al., 2004).”
BackgroundInfluentialYano, H., & Moran, B. J. (2007) · British journal of surgery · doi:10.1002/bjs.6061 · Cited by 144
Carruthers, R., Tho, L. M., Brown, J., Kakumanu, S., McCartney, E., & McDonald, A. C. (2012) · Colorectal Disease · doi:10.1111/j.1463-1318.2012.03147.x · Cited by 153
Haddock, M. G., Miller, R. C., Nelson, H., Pembérton, J. H., Dozois, E. J., Alberts, S. R., & Gunderson, L. L. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.10.046 · Cited by 137
Wang, G., Li, Z., Zhao, Q., Zhu, Y., Zhao, C., LI, X., Ma, Z., Li, X., & Zhang, Y. (2014) · Oncology Reports · doi:10.3892/or.2014.3047 · Cited by 138
miR-145 Antagonizes SNAI1-Mediated Stemness and Radiation Resistance in Colorectal Cancer
Zhu, Y., Wang, C., Becker, S. A., Hurst, K. E., Nogueira, L. M., Findlay, V. J., & Camp, E. R. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.12.023 · Cited by 139
Posterior urethral complications of the treatment of prostate cancer
Mundy, A. R., & Andrich, D. E. (2012) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10864.x · Cited by 144
Kim, I.-J., Lim, S., Kang, H. C., Chang, H. J., Ahn, S.-A., Park, H., Jang, S., Park, J.-H., Kim, D. Y., Jung, K. H., et al. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-277-7 · Cited by 137
Maretto, I., Pomerri, F., Pucciarelli, S., Mescoli, C., Belluco, E., Burzi, S., Rugge, M., Muzzio, P. C., & Nitti, D. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9269-4 · Cited by 136
“Total mesorectal excision surgery is a widely accepted treatment for mid to low rectal cancer, although for locally advanced rectal cancer, combined treatments are required.(1,2) Traditionally, the pretreatment local staging for rectal cancer includes digital rectal assessment, proctoscopy, transrectal ultrasonography…”
BackgroundUehara, K., Hiramatsu, K., Maeda, A., Sakamoto, E., Inoue, M., Kobayashi, S., Tojima, Y., Yoshioka, Y., Nakayama, G., Yatsuya, H., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt115 · Cited by 142
Rimkus, C., Friederichs, J., Boulesteix, A., Theisen, J., Mages, J., Becker, K., Nekarda, H., Rosenberg, R., Janssen, K., & Siewert, J. R. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2007.10.022 · Cited by 141
Czito, B. G., Bendell, J. C., Willett, C. G., Morse, M. A., Blobe, G. C., Tyler, D. S., Thomas, J., Ludwig, K. A., Mantyh, C. R., Ashton, J., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.02.001 · Cited by 134
Yasuda, K., Nirei, T., Sunami, E., Nagawa, H., & Kitayama, J. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-49 · Cited by 152
“Recently, adding chemotherapy to RT (CRT) has achieved even more favorable results [1-3].”
BackgroundRectal Carcinoma: MRI with Histologic Correlation Before and After Chemoradiation Therapy
Allen, S. D., Padhani, A. R., Dzik-Jurasz, A. S. K., & Glynne‐Jones, R. (2007) · American Journal of Roentgenology · doi:10.2214/ajr.05.1967 · Cited by 134
“To our knowledge, this finding has not been specifically reported, although this tumor subtype is well recognized as a radiologic entity [15, 29] and is accepted as having an overall poorer outcome than other histologic subtypes [30, 31].”
BackgroundWatch and wait approach in rectal cancer: Current controversies and future directions
López‐Campos, F., Martín, M., Pérez, R. F., Pérez, J. C. G., Trill, J. D., Fuentes-Mateos, R., López-Durán, S., Domínguez-Rullán, J. A., Ferreiro, R., Riquelme-Oliveira, A., et al. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i29.4218 · Cited by 145
Guillem, J. G., Chessin, D. B., Shia, J., Suriawinata, A. A., Riedel, E., Moore, H. G., Minsky, B. D., & Wong, W. D. (2006) · Annals of Surgery · doi:10.1097/01.sla.0000232540.82364.43 · Cited by 134
“Preoperative combined modality therapy (CMT) has been shown to improve local control and sphincter preservation rates in patients with locally advanced rectal cancer endorectal ultrasound (ERUS) T3–T4 and/or N1 or clinically bulky .(7) We recently reported that sphincter preservation rates of over 70% may be achieved…”
BackgroundBujko, K., Glimelius, B. L. G., Valentini, V., Michalski, W., & Spalek, M. J. (2015) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2015.03.233 · Cited by 135
Du, D., Su, Z., Wang, D., Liu, W., & Wei, Z. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.10.012 · Cited by 159
“This approach is associated with improved overall survival (OS) and reduced incidence of LR.(11,12)”
BackgroundStelzner, S., Koehler, C., Stelzer, J., Sims, A., & Witzigmann, H. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1235-3 · Cited by 140
“After introduction of TME, survival in patients with rectal cancer was largely determined by systemic rather than local relapse [50, 115].”
BackgroundColorectal cancer susceptibility loci as predictive markers of rectal cancer prognosis after surgery
Hu, Y., Gaedcke, J., Emons, G., Beißbarth, T., Grade, M., Jo, P., Yeager, M., Chanock, S. J., Wolff, H. A., Camps, J., et al. (2017) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22512 · Cited by 136
“While colon cancers are usually surgically removed and then treated with adjuvant chemotherapy, the standard treatment for locally advanced rectal cancers consists of a preoperative chemoradiotherapy (CRT) (Rodel et al, 2012a; Sauer et al, 2004) followed by a total mesorectal excision of the tumor.”
BackgroundMethodPerez, R. O., Habr‐Gama, A., Pereira, G. V., Lynn, P. B., Alves, P., Proscurshim, I., Rawet, V., & Gama‐Rodrigues, J. (2011) · Colorectal Disease · doi:10.1111/j.1463-1318.2011.02761.x · Cited by 131
Paoli, A. D., Chiara, S., Luppi, G., Friso, M. L., Beretta, G. D., Prete, S. D., Pasetto, L. M., Santantonio, M. L., Sarti, E., Mantello, G., et al. (2005) · Annals of Oncology · doi:10.1093/annonc/mdj041 · Cited by 133
“Cionini L, Cartei F, Manfredi B et al. Randomised study of preoperative chemoradiation (CT–RT) in locally advanced rectal cancer.”
InfluentialSurgical Management of Pulmonary Metastases from Colorectal Cancer in 153 Patients
Yedibela, S., Klein, P., Feuchter, K., Hoffmann, M., Meyer, T., Papadopoulos, T., Göhl, J., & Hohenberger, W. (2006) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9100-2 · Cited by 130
Self-citationKrabbamein í ristli og endaþarmi - yfirlitsgrein
Haraldsdóttir, S., Einarsdóttir, H. M., Smáradóttir, A., Gunnlaugsson, A., Halfdanarson, T. R., & Hálfdánarson, Þ. R. (2014) · Læknablaðið · doi:10.17992/lbl.2014.02.531 · Cited by 146
Pelvic radiation therapy: Between delight and disaster
Morris, K. A. L., & Haboubi, N. Y. (2015) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v7.i11.279 · Cited by 152
Metadata
- Authors
- Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., Karstens, J.-H., Liersch, T., Schmidberger, H., & Raab, R.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Leipzig University (DE)
- University of Rostock (DE)
- Charité – Universitätsmedizin Berlin (DE)
- Hospital of the Brothers of St. John of God (AT)
- Klinikum Klagenfurt (AT)
- University of Göttingen (DE)
- Medizinische Hochschule Hannover (DE)
- Klinikum Oldenburg (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-10-21
- Volume
- 351
- Issue
- 17
- Pages
- 1731-1740
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2125452425
- Cited by
- 6,050
- References
- 19
- Citations by year
- 2026: 178 · 2025: 205 · 2024: 232 · 2023: 275 · 2022: 310 · 2021: 324 · 2020: 322 · 2019: 321 · 2018: 305 · 2017: 298 · 2016: 291 · 2015: 348 · 2014: 340 · 2013: 333 · 2012: 346
- FWCI
- 82.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- GRO (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Surgery › Colorectal and Anal Carcinomas
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- rectal cancer, locally advanced rectal cancer, neoadjuvant chemoradiotherapy, postoperative chemoradiotherapy, neoadjuvant therapy, adjuvant therapy, 5-fluorouracil, boost radiotherapy, local recurrence, overall survival, treatment toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Combined Modality Therapy, Female, Fluorouracil, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Postoperative Care, Postoperative Complications, Preoperative Care, Quality Control, Radiotherapy, Rectal Neoplasms, Incidence, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.